This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
NCT ID: NCT05935085
Last Updated: 2025-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
201 participants
INTERVENTIONAL
2023-06-13
2025-01-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT03533751
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT05048056
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
NCT07205081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ANB032 SC Dose 1
This arm will receive treatment SC
ANB032
BTLA agonist antibody
ANB032 SC Dose 2
This arm will receive treatment SC
ANB032
BTLA agonist antibody
ANB032 SC Dose 3
This arm will receive treatment SC
ANB032
BTLA agonist antibody
Placebo
This arm will receive Placebo SC
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ANB032
BTLA agonist antibody
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe AD for at least 6 months prior to Randomization
* History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
* EASI score ≥ 16 at Screening and at Randomization
* vIGA AD score ≥ 3 at Screening and at Randomization
* AD involved BSA ≥ 10% at Screening and at Randomization
Exclusion Criteria
* Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status
* Not able to tolerate SC drug administration
* Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AnaptysBio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Rigby, MD
Role: STUDY_DIRECTOR
AnaptysBio, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AnaptysBio Investigative Site 10-140
Anaheim, California, United States
AnaptysBio Investigative Site 10-141
Cerritos, California, United States
AnaptysBio Investigative Site 10-121
Fountain Valley, California, United States
AnaptysBio Investigative Site 10-107
Fremont, California, United States
AnaptysBio Investigative Site 10-120
Lancaster, California, United States
AnaptysBio Investigative 10-125
Lomita, California, United States
AnaptysBio Investigative Site 10-146
Oxnard, California, United States
AnaptysBio Investigative Site 10-147
Pasadena, California, United States
AnaptysBio Investigative Site 10-112
Santa Monica, California, United States
AnaptysBio Investigative Site 10-136
Doral, Florida, United States
AnaptysBio Investigative Site 10-133
Miami, Florida, United States
AnaptysBio Investigative Site 10-116
Miami, Florida, United States
AnaptysBio Investigative Site 10-134
Miami, Florida, United States
AnaptysBio Investigative Site 10-106
Miami, Florida, United States
AnaptysBio Investigative Site 10-122
Atlanta, Georgia, United States
AnaptysBio Investigative Site 10-130
Boise, Idaho, United States
AnaptysBio Investigative Site 10-151
Flossmoor, Illinois, United States
AnaptysBio Investigative Site 10-127
Clarksville, Indiana, United States
AnaptysBio Investigative Site 10-149
Merrillville, Indiana, United States
AnaptysBio Investigative Site 10-128
New Albany, Indiana, United States
AnaptysBio Investigative Site 10-137
Baton Rouge, Louisiana, United States
AnaptysBio Investigative Site 10-131
Methuen, Massachusetts, United States
AnaptysBio Investigative Site 10-126
Ann Arbor, Michigan, United States
AnaptysBio Investigative Site 10-139
Auburn Hills, Michigan, United States
AnaptysBio Investigative Site 10-114
Detroit, Michigan, United States
AnaptysBio Investigative Site 10-138
Troy, Michigan, United States
AnaptysBio Investigative Site 10-150
Hazelwood, Missouri, United States
AnaptysBio Investigative Site 10-110
Saint Joseph, Missouri, United States
AnaptysBio Investigative Site 10-148
Las Vegas, Nevada, United States
AnaptysBio Investigative Site 10-109
Charlotte, North Carolina, United States
AnaptysBio Investigative Site 10-108
Wilmington, North Carolina, United States
AnaptysBio Investigative Site 10-129
Mason, Ohio, United States
AnaptysBio Investigative Site 10-113
Portland, Oregon, United States
AnaptysBio Investigative Site 10-145
Philadelphia, Pennsylvania, United States
AnaptysBio Investigative Site 10-119
Nashville, Tennessee, United States
AnaptysBio Investigative Site 10-144
Baytown, Texas, United States
AnaptysBio Investigative Site 10-124
Dallas, Texas, United States
AnaptysBio Investigative Site 10-105
Frisco, Texas, United States
AnaptysBio Investigative Site 10-142
Katy, Texas, United States
AnaptysBio Investigative Site 10-104
San Antonio, Texas, United States
AnaptysBio Investigative Site 10-132
Spokane, Washington, United States
AnaptysBio Investigative Site 35-103
Woolloongabba, Queensland, Australia
AnaptysBio Investigative Site 35-104
Coorparoo, , Australia
AnaptysBio Investigative Site 11-105
Surrey, British Colombia, Canada
AnaptysBio Investigative Site 11-102
Barrie, Ontario, Canada
AnaptysBio Investigative Site 11-106
Etobicoke, Ontario, Canada
AnaptysBio Investigative Site 11-101
London, Ontario, Canada
AnaptysBio Investigative Site 11-103
North Bay, Ontario, Canada
AnaptysBio Investigative Site 11-107
Richmond Hill, Ontario, Canada
AnaptysBio Investigative Site 57-104
Pardubice, , Czechia
AnaptysBio Investigative Site 57-105
Prague, , Czechia
AnaptysBio Investigative Site 57-102
Prague, , Czechia
AnaptysBio Investigative Site 57-101
Prague, , Czechia
AnaptysBio Investigative Site 59-105
Tbilisi, , Georgia
AnaptysBio Investigative Site 59-106
Tbilisi, , Georgia
AnaptysBio Investigative Site 59-101
Tbilisi, , Georgia
AnaptysBio Investigative Site 59-102
Tbilisi, , Georgia
AnaptysBio Investigative Site 59-103
Tbilisi, , Georgia
AnaptysBio Investigative Site 59-104
Tbilisi, , Georgia
AnaptysBio Investigative Site 59-107
Tbilisi, , Georgia
AnaptysBio Investigative Site 36-101
Grafton, , New Zealand
AnaptysBio Investigative Site 36-104
Nelson, , New Zealand
AnaptysBio Investigative Site 36-102
Rosedale, , New Zealand
AnaptysBio Investigative Site 36-103
Wellington, , New Zealand
AnaptysBio Investigative Site 30-111
Bydgoszcz, , Poland
AnaptysBio Investigative Site 30-113
Częstochowa, , Poland
AnaptysBio Investigative Site 30-108
Gdansk, , Poland
AnaptysBio Investigative Site 30-106
Krakow, , Poland
AnaptysBio Investigative Site 30-101
Lodz, , Poland
AnaptysBio Investigative Site 30-109
Rzeszów, , Poland
AnaptysBio Investigative Site 30-115
Skierniewice, , Poland
AnaptysBio Investigative Site 30-112
Szczecin, , Poland
AnaptysBio Investigative Site 30-102
Świdnik, , Poland
AnaptysBio Investigative Site 30-105
Warsaw, , Poland
AnaptysBio Investigative Site 30-107
Warsaw, , Poland
AnaptysBio Investigative Site 30-116
Warsaw, , Poland
AnaptysBio Investigative Site 30-104
Wroclaw, , Poland
AnaptysBio Investigative Site 30-114
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANB032-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.